The Expert Angle

Medlior is a well-known and trusted industry leader.

Our team is dedicated to delivering high-quality research that provides a solid basis for informed decision-making.

Medlior’s Expert Angle offers the inside track on new studies, industry hot topics, and what you need to know in the fast-paced world of clinical research, all from the point of view of the Medlior team of experts. From the latest topics and trends to the foundations of health and medical research, Medlior explores topics relevant to clients and the world.

Case Study: Multiple Myeloma

Case Study: Multiple Myeloma

Medlior Health Outcomes Research was engaged by Celgene Canada (now a subsidiary of Bristol-Myers Squibb Company) to examine the treatment landscape for patients with multiple myeloma (MM) and the effects of lenalidomide (REVLMID®) as an immunomodulatory imide drug for both newly-diagnosed MM patients and relapsed/refractory MM patients. 
Lipid-lowering Therapy Patterns and Low-density Lipoprotein-Cholesterol Management Among Patients with Acute Myocardial Infarction in Alberta, Canada

Lipid-lowering Therapy Patterns and Low-density Lipoprotein-Cholesterol Management Among Patients with Acute Myocardial Infarction in Alberta, Canada

Medlior’s presentation focuses on a real-world evidence study sponsored by Amgen Inc. examining the management of patients with an acute myocardial infarction (AMI) in Alberta, Canada. AMI is a leader in disease burden and death worldwide. In order to combat AMI, modifiable factors that lower cholesterol, specifically low-density lipoprotein-cholesterol (LDL-C) are needed. Therapies designed to lower LDL-C, such as statins, also called lipid lowering therapies (LLT), are therefore important to understand the patterns of use and to what extent LDL-C is lowered. Medlior’s study utilized health system data to explore the patterns of LLT and the management of LDL-C levels in patients who experienced AMI.
Canadian real-world evidence on epidemiology, outcomes and economics of moderate-to-severe osteoarthritis

Canadian real-world evidence on epidemiology, outcomes and economics of moderate-to-severe osteoarthritis

A systematic literature review Osteoarthritis (OA) is a chronic joint disease that leads to a loss of articular cartilage, resulting in painful bone-on-bone contact. Females have a higher risk of developing OA compared to males, and obese individuals are three times more likely to develop OA. ...
Coronavirus background and key questions

Coronavirus background and key questions

As the COVID-19 virus spreads, world governments implement control strategies This article is about an emerging and rapidly evolving public health crisis. Case and death counts change daily. If you’re interested in learning the very latest information please consult the World Health ...
Medlior partners with Calgary Universities for proof-of-concept study 

Medlior partners with Calgary Universities for proof-of-concept study 

Study on natural language processing and machine learning to develop oncology decision aid for multiple myeloma in Alberta In Canada, approximately 2,900 people were diagnosed with multiple myeloma in 2017. Unique, targeted therapies are currently in development for multiple myeloma and will ...
Industry Predictions for 2020

Industry Predictions for 2020

Medlior is looking forward to a year of innovation in health outcomes research with Real World Evidence leading the way. See our predictions for 2020.
Looking Back on 2019

Looking Back on 2019

2019 has proven to be a great year for Medlior, the healthcare industry and Real World Evidence. Read our wrap on the last year here.
Using Integrated Real-World Data in Alberta to Develop Personalized Follow-up Care Pathways for Cancer Survivors

Using Integrated Real-World Data in Alberta to Develop Personalized Follow-up Care Pathways for Cancer Survivors

This study will provide an integrated data source to inform follow-up clinical care pathways for cancer survivors in Alberta The odds of long-term recovery from cancer have never been better. In the 1940s only 25% of Canadians survived a cancer diagnosis, compared with 60% ...
Real World Data and Inflammatory Bowel Disease

Real World Data and Inflammatory Bowel Disease

Real World Data could be used to create a better understanding of the burden of diseases such as inflammatory bowel disease and improve health outcomes
Real World Data can impact economic analyses of Huntington’s Disease

Real World Data can impact economic analyses of Huntington’s Disease

Studies on the costs of Huntington’s Disease are lacking in Canada. A real-world evidence study will be vital to future economic analyses.
Estimating the burden of illness of obesity in Alberta

Estimating the burden of illness of obesity in Alberta

Obesity has traditionally been considered a result of lifestyle factors, including poor diet and physical inactivity, and thus, it has been considered a preventable condition. However, the Canadian Medical Association has recently declared obesity to be a chronic medical disease due to the associated negative health effects.9 While lifestyle modifications can prevent obesity in some, further pharmaceutical intervention is required to mitigate the growing obesity epidemic in Canada and reduce the national burden of disease.
Insights into how Real World Radar can improve research

Insights into how Real World Radar can improve research

Real World Radar by Medlior, houses real world databases from across the world. Real world data provides chances for real world evidence to improve care